ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2012

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.

Anas Younes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.